AstraZeneca fluffs its lines on emerging markets
16 March 2010
Christopher Spillane
AstraZeneca has hastily rewritten expectations for its business in emerging markets, an area of key growth if it is to prosper after several key products lose patent protection in its core markets.
In little over a month, the UK firm has scaled back the anticipated boon to its business of sales...
Please Login to read the full article.
16 March 2010
Christopher Spillane
In little over a month, the UK firm has scaled back the anticipated boon to its business of sales...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
- Justice chief: US taking 'bold' steps to fight counterfeiters, IP thieves
- IMI plans "unprecedented" programme for novel antibiotics as drug resistance continues to rise
- HHS chief: Supreme Court decision needed to assure states on exchanges
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
